trial
as of 2026-07-01OXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With Schizophrenia
NCTId NCT06136390
at a glance
— · Completed
Enrollment 42 (actual)
Sponsored by Charite University, Berlin, Germany
Primary completion 2024-12-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Completed
Enrollment
42 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2023-09-30
Primary completion
2024-12-30
Eligibility
ALL · 18 Years · 75 Years
Interventions & indications
Drugs
Indications
Sponsors
Charite University, Berlin, GermanyLead Sponsor
Investigators
3
Marco Zierhut, Dr.Principal Investigator
Kerem Böge, PDPrincipal Investigator
Eric Hahn, PDPrincipal Investigator
Sites
1 total
Berlin, Germany
Facts & assertions
4 sourced
Enrollment
42
Phase
NA
Primary Completion Date
2024-12-30
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
indication
investigator